Loading
Life sciences · Journal article
Nutrition and Health · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Apolipoprotein L1 (APOL1) genetic variants are associated with the development of chronic kidney disease (CKD), but disease expression appears to depend on metabolic and environmental modifiers. Obesity is a risk factor for several chronic diseases. However, the relationship between obesity, body fat, and the development of kidney disease mediated by APOL1 risk variants is unknown. Aim: This study examined relationships among APOL1 risk variants, nutritional status, with a focus on anthropometry and body composition, and selected renal function biomarkers in individuals with CKD. Methods: Adults with CKD were genotyped for APOL1 variants, resulting in APOL1 risk and APOL1 non-risk groups. Results: The APOL1 risk group showed higher body mass index, increased central abdominal fat, and greater body fat compared with established reference values ( p < 0.05). This group also showed high serum creatinine levels and a low estimated glomerular filtration rate, both abnormal ranges ( p < 0.05). Conclusions: These findings demonstrate excessive body and abdominal fat as a relevant target for precision nutrition strategies to reduce CKD risk and support management in APOL1-associated kidney disease. Also, it is necessary to identify carriers before the onset of CKD and to use medical nutrition therapy to prevent or delay disease progression.